NeurAxis, Inc. (NRXS) AMEX
8.35
+0.44(+5.56%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.35
+0.44(+5.56%)
Currency In USD
| Previous Close | 7.91 |
| Open | 7.95 |
| Day High | 8.46 |
| Day Low | 7.75 |
| 52-Week High | 9.33 |
| 52-Week Low | 2.07 |
| Volume | 202,183 |
| Average Volume | 193,750 |
| Market Cap | 103.41M |
| PE | -10.44 |
| EPS | -0.8 |
| Moving Average 50 Days | 7.33 |
| Moving Average 200 Days | 4.37 |
| Change | 0.44 |
NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
Total national coverage footprint for PENFS increases to roughly 100 million covered livesCARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializi
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adult